The natural history of hepatitis C with severe hepatic fibrosis

Lawson, Adam; Hagan, Simone; Rye, Kara; Taguri, Nader; Ratib, Sonia; Zaitoun, Abed M.; Neal, Keith; Ryder, Stephen; Irving, William L.

doi:10.1016/j.jhep.2007.02.010

Cited by 48 publications

(38 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a multivariate analysis, combination therapy with IFN and ribavirin was associated with improved survival, most notably among sustained responders. 17 Available evidence also suggests that even patients with compensated liver cirrhosis who achieve SVR may experience beneficial alterations of their disease course. For example, in a multicenter cohort of 920 Italian patients with histologically proven HCV-derived cirrhosis treated with IFN monotherapy, a significant reduction in the rates of liver-related complications, hepatocellular carcinoma, and liver-related mortality was found in patients who achieved an SVR compared with those who did not.…”

Section: Discussionmentioning

confidence: 99%

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

et al. 2009

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

et al. 2009

View full text Add to dashboard Cite

“…However, the role of fibrosis concerning pathogenesis of HCC is still discussed controversially. [20][21][22] Our analysis of the functional role of TLR2 -196 to -174 del/ins alleles with respect to TLR2 expression was based on in vitro stimulation studies. However, our in vitro findings are supported by increased TLR2 expression reported for mononuclear cells in the peripheral blood 23 and livers of HCV-infected patients.…”

Section: Short Reportmentioning

confidence: 99%

The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C

Nischalke

Coenen

Berger

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is a major risk factor for hepatocellular carcinoma (HCC). HCV proteins core and NS3 can bind to toll-like receptor 2 (TLR2) and trigger inflammatory responses. Polymorphisms in the TLR2 gene predispose to various forms of malignancy but have not been studied in HCV-associated HCC. Here, we investigated whether single nucleotide polymorphisms (SNPs), rs4696480, rs5743708, rs5743704 and the -196 to -174 del/ins polymorphism of the TLR2 gene affect the risk for HCC in chronic hepatitis C. The study involved 189 and 192 HCV genotype 1 infected patients with and without HCC, respectively, as well as 347 healthy controls. TLR2 alleles were determined by hybridization probe assays and allele-specific short fragment polymerase chain reaction on a LightCycler system. All TLR2 polymorphisms matched the HardyWeinberg equilibrium in each study group. Although TLR2 SNPs showed no effect, the frequency of the TLR2 -196 to -174 del allele was significantly higher in patients with HCV-associated HCC (22.5%) than in HCV-infected patients without HCC (15.6%, p 5 0.016) and healthy controls (15.3%, p 5 0.003). HCV-infected carriers of a TLR2 -196 to -174 del allele had significantly higher HCV viral loads than TLR2 -196 to -174 ins/ins homozygous patients (p 5 0.031). Finally, in carriers of the TLR2 -196 to -174 del allele, stimulation of monocytes resulted in significantly lower TLR2 expression levels and interleukin-8 (IL-8) induction than in individuals with the TLR2 -196 to -174 ins/ins genotype (p < 0.05). Our data suggest the TLR2 -196 to -174 del allele to affect HCV viral loads and to increase the risk for HCC in HCV genotype1-infected patients.

show abstract

“…Chronic HCV infection may eventually progress to severe fibrosis or cirrhosis, which necessitates surveillance for hepatocellular carcinoma and screening for varices (2). A natural history study revealed that a quarter of patients with chronic hepatitis C (CHC) with severe liver fibrosis succumbed after a median interval of 3.5 years, although this poor prognosis was improved following combination antiviral treatment (3). Therefore, the evaluation of severe hepatic fibrosis involves assessing the prognosis of, and developing a treatment strategy for, patients with CHC.…”

Section: Introductionmentioning

confidence: 99%

Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C

Zheng

et al. 2012

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. The plasma profile of sphingolipids in hepatic fibrosis patients with chronic hepatitis C (CHC) is rarely considered at present. The association between plasma sphingolipids and severe fibrosis in CHC remains an obscure area of research. The aim of the present study was to assess the plasma profile of sphingolipids and to examine the association between plasma sphingolipids and severe fibrosis in CHC, in order to identify potential novel markers of severe fibrosis in CHC. A cohort of 120 treatment-naïve patients with CHC were included in the present study. Liver biopsies were performed and routine serological indicators were measured. Plasma sphingolipids were detected using high performance liquid chromatography tandem mass spectrometry. A total of 44 plasma sphingolipids were detected. Plasma hexosylceramide (HexCer; d18:1/12:0), HexCer (d18:1/16:0) and HexCer (d18:1/22:0) were shown to

show abstract

The natural history of hepatitis C with severe hepatic fibrosis

Cited by 48 publications

References 29 publications

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C

Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C

Contact Info

Product

Resources

About